Rédaction Africa Links 24 with Damian Garde
Published on 2024-03-21 12:48:39
Biotech is an industry that is constantly evolving, and staying informed on the latest developments is crucial. From new treatments to financial challenges, there is always something happening in the world of biotechnology.
One recent development involves Roche and its partner Chugai, who reported that their IL-6-targeted antibody treatment, Enspryng, did not meet expectations in a Phase 3 study for the autoimmune disorder myasthenia gravis. This news had a ripple effect on other companies in the space, with shares of Argenx, Immunovant, and Tourmaline Bio reacting to the setback.
Another notable event is the launch of Mirador Therapeutics, a new startup led by the team behind Prometheus Therapeutics. With a focus on developing new medicines for inflammatory diseases, Mirador recently raised $400 million to support its mission.
Intra-Cellular Therapies is also generating buzz as it prepares to release Phase 3 data on its lead drug for major depressive disorder next month. MDD has been a challenging area for drug development, but Intra-Cellular’s treatment, already approved for other conditions, may offer new hope for patients.
Meanwhile, the U.K. is exploring the concept of n-of-1 medicine, which involves creating personalized therapies for patients with rare conditions. While this approach shows promise, there are still challenges to overcome in terms of research, regulation, and funding.
In the financial realm, BioNTech, known for its work on the Covid-19 vaccine with Pfizer, is experiencing a downturn in its stock price after reporting disappointing financials. The company is now looking to its oncology pipeline to offset the decline in Covid vaccine revenue.
These are just a few of the latest happenings in the biotech world. From new startups to clinical trial results, the industry is constantly moving forward with new innovations and challenges. Stay informed by signing up for our biotech newsletter to ensure you don’t miss out on the latest updates.
